Gene Signal International SA

Swiss biotech Gene Signal International SA has learned the hard way that when you have a first-in-class compound that’s the first potential therapy for a specific indication, the primary endpoint

IN VITRO DIAGNOSTICS Drug Response Dx GMBH Drug Response Dx closes Series A round Start-up diagnostics firm Drug Response Dx GMBH has raised an undisclosed amount in its Series A financing to

Swiss angiogenesis company Gene Signal International SA expects to complete a Phase III study of its lead ophthalmic antisense compound, aganirsen, for preventing corneal graft rejection by the mi

Having completed its latest private funding round, Lausanne, Switzerland-based biotech firm, Gene Signal said it is set to embark on an 'aggressive' three-year clinical and commercialization plan for